Okogen Inc. has submitted a regulatory application to India's Central Drugs Standard Control Organization (CDSCO) for its Phase IIb clinical trial, the Emerald Study, marking a critical milestone in the company's effort to develop an innovative treatment for acute infectious conjunctivitis (AIC).
The study, scheduled during the 2025 Monsoon Season when conjunctivitis rates peak, aims to evaluate OKG-0303, a triple-combination eyedrop targeting both bacterial and viral forms of the disease. Simultaneously, the company appointed Dr. David A. Hollander as its new Chief Medical Officer, bringing extensive experience in drug development and regulatory affairs.
The global conjunctivitis market represents a significant healthcare challenge, currently valued at $4.2 billion annually and projected to grow beyond $6 billion by 2031. Notably, there are currently no approved treatments for adenoviral conjunctivitis, which comprises over 90% of viral ocular infections.
Dr. Hollander highlighted the study's importance, emphasizing the challenges healthcare providers face in accurately diagnosing and treating conjunctivitis while preventing its spread. His expertise, including previous leadership roles at Revance, Aerie Pharmaceuticals, and Allergan, positions Okogen to potentially transform AIC treatment.
Okogen's CEO, Joshua Moriarty, characterized the CDSCO submission as a significant step toward delivering a unique platform for managing AIC. The company expects a data readout in Q4 2025 and is concurrently developing an AI-powered evaluation tool to improve patient care.
The Emerald Study represents a potentially groundbreaking approach to addressing a widespread medical condition, combining innovative pharmaceutical development with advanced technological solutions.
